A detailed history of Stephens Investment Management Group LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Stephens Investment Management Group LLC holds 1,932,209 shares of SUPN stock, worth $68.8 Million. This represents 0.85% of its overall portfolio holdings.

Number of Shares
1,932,209
Previous 1,898,499 1.78%
Holding current value
$68.8 Million
Previous $50.8 Million 18.63%
% of portfolio
0.85%
Previous 0.73%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$25.77 - $35.16 $868,706 - $1.19 Million
33,710 Added 1.78%
1,932,209 $60.2 Million
Q2 2024

Aug 06, 2024

SELL
$25.99 - $33.85 $85,169 - $110,926
-3,277 Reduced 0.17%
1,898,499 $50.8 Million
Q1 2024

May 14, 2024

SELL
$27.11 - $35.17 $83,715 - $108,604
-3,088 Reduced 0.16%
1,901,776 $64.9 Million
Q4 2023

Feb 13, 2024

BUY
$22.72 - $29.68 $4.55 Million - $5.94 Million
200,166 Added 11.74%
1,904,864 $55.1 Million
Q3 2023

Nov 14, 2023

BUY
$27.57 - $32.91 $109,811 - $131,080
3,983 Added 0.23%
1,704,698 $47 Million
Q2 2023

Aug 14, 2023

BUY
$29.91 - $38.73 $1.15 Million - $1.49 Million
38,453 Added 2.31%
1,700,715 $51.1 Million
Q1 2023

May 15, 2023

BUY
$34.93 - $42.03 $2.01 Million - $2.42 Million
57,493 Added 3.58%
1,662,262 $60.2 Million
Q4 2022

Jan 26, 2023

SELL
$31.09 - $37.88 $32,240 - $39,281
-1,037 Reduced 0.06%
1,604,769 $57.6 Million
Q3 2022

Nov 07, 2022

SELL
$28.79 - $35.41 $189,323 - $232,856
-6,576 Reduced 0.41%
1,605,806 $54.4 Million
Q2 2022

Aug 03, 2022

BUY
$25.33 - $34.25 $279,592 - $378,051
11,038 Added 0.69%
1,612,382 $46.6 Million
Q1 2022

May 04, 2022

BUY
$28.51 - $32.9 $666,107 - $768,675
23,364 Added 1.48%
1,601,344 $51.8 Million
Q4 2021

Feb 15, 2022

BUY
$26.37 - $34.22 $8.91 Million - $11.6 Million
337,902 Added 27.25%
1,577,980 $46 Million
Q3 2021

Oct 27, 2021

SELL
$23.54 - $31.39 $123,608 - $164,828
-5,251 Reduced 0.42%
1,240,078 $33.1 Million
Q2 2021

Aug 09, 2021

BUY
$26.72 - $33.19 $2.8 Million - $3.48 Million
104,810 Added 9.19%
1,245,329 $38.3 Million
Q1 2021

May 14, 2021

BUY
$24.15 - $31.45 $7.13 Million - $9.28 Million
295,141 Added 34.91%
1,140,519 $29.9 Million
Q4 2020

Feb 10, 2021

BUY
$17.7 - $25.81 $9.68 Million - $14.1 Million
546,738 Added 183.08%
845,378 $21.3 Million
Q3 2020

Nov 13, 2020

BUY
$20.2 - $25.05 $590,203 - $731,910
29,218 Added 10.84%
298,640 $6.22 Million
Q2 2020

Aug 24, 2020

SELL
$17.09 - $24.89 $196,962 - $286,857
-11,525 Reduced 4.1%
269,422 $6.4 Million
Q1 2020

May 14, 2020

BUY
$14.45 - $24.69 $12,918 - $22,072
894 Added 0.32%
280,947 $5.05 Million
Q4 2019

Feb 14, 2020

SELL
$19.93 - $29.13 $123,147 - $179,994
-6,179 Reduced 2.16%
280,053 $6.64 Million
Q3 2019

Oct 18, 2019

SELL
$25.47 - $33.37 $519,333 - $680,414
-20,390 Reduced 6.65%
286,232 $7.87 Million
Q2 2019

Aug 01, 2019

BUY
$29.96 - $38.87 $2.89 Million - $3.75 Million
96,494 Added 45.92%
306,622 $10.1 Million
Q1 2019

May 03, 2019

SELL
$32.77 - $41.99 $21,726 - $27,839
-663 Reduced 0.31%
210,128 $7.36 Million
Q4 2018

Feb 11, 2019

BUY
$30.84 - $49.51 $1.11 Million - $1.79 Million
36,150 Added 20.7%
210,791 $7 Million
Q3 2018

Nov 14, 2018

SELL
$42.7 - $56.55 $537,550 - $711,907
-12,589 Reduced 6.72%
174,641 $8.79 Million
Q2 2018

Aug 10, 2018

BUY
$44.1 - $59.85 $204,183 - $277,105
4,630 Added 2.54%
187,230 $10.9 Million
Q1 2018

May 04, 2018

SELL
$37.15 - $46.9 $36,889 - $46,571
-993 Reduced 0.54%
182,600 $8.36 Million
Q4 2017

Feb 05, 2018

BUY
$36.4 - $42.6 $6.68 Million - $7.82 Million
183,593
183,593 $7.32 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.9B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Stephens Investment Management Group LLC Portfolio

Follow Stephens Investment Management Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Investment Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stephens Investment Management Group LLC with notifications on news.